U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335328) titled 'Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies' on Jan. 05.
Brief Summary: This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.
Study Start Date: May 01, 2026
Study Type: INTERVENTIONAL
Condition:
B-cell Non Hodgkin Lymphoma
Intervention:
BIOLOGICAL: 1 X 10^6 cells/kg
Dose escalation: CAR-T cells will be administered at one of two dose levels either fresh or thawed after cryopreservation by IV injection.
BIO...